^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BA1104 (nivolumab biosimilar)
i
Other names: BA1104, LY01015, LY-01015
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Luye Group
Drug class:
PD1 inhibitor
Related drugs:
2ms
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
P3, N=510, Recruiting, Shandong Boan Biotechnology Co., Ltd | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Opdivo (nivolumab) • cisplatin • 5-fluorouracil • BA1104 (nivolumab biosimilar)
8ms
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
P3, N=510, Not yet recruiting, Shandong Boan Biotechnology Co., Ltd
New P3 trial • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Opdivo (nivolumab) • cisplatin • 5-fluorouracil • BA1104 (nivolumab biosimilar)
Share via
